FiberNEW2026-09

Decoding dysbiosis: the role of gut microbiota in MASLD progression and emerging therapeutic interventions.

Swamikkannu Dinesh Mohan, Dasarapu Santhosha, Mohan Kanishk Dinesh, Shanmugam Allimalarkodi — Journal of physiology and biochemistry

Summary

Our gut bacteria play a vital role in overall health, and an imbalance in these microbes, known as dysbiosis, is increasingly linked to a common liver condition called Metabolic dysfunction-associated steatotic liver disease (MASLD). This scientific review highlights how an unhealthy gut microbiome can contribute to MASLD progression and suggests that targeting these gut bacteria, potentially through dietary fiber (prebiotics) or other interventions, could offer new ways to diagnose and treat the disease.

AI-generated summary — read the original

Key points

An imbalance in gut bacteria, called dysbiosis, is closely linked to the development and worsening of MASLD, a common liver disease.
This unhealthy gut microbiome can contribute to liver inflammation and metabolic issues, driving the disease forward.
Future strategies for MASLD might involve restoring a healthy gut bacterial balance, potentially through specific dietary components like prebiotics.
Analyzing a person's gut bacteria could also become a way to detect MASLD earlier.

What the study looked at

This scientific review explored how the balance of bacteria in our gut influences the development and progression of Metabolic dysfunction-associated steatotic liver disease (MASLD), a common liver condition. It also looked at potential new ways to diagnose and treat MASLD by focusing on these gut bacteria. This was a review paper, meaning the researchers synthesized findings from many existing studies. They didn't conduct new experiments on participants but rather analyzed published scientific literature to understand the current knowledge on the gut microbiota's role in MASLD. The review found that an unhealthy imbalance in gut bacteria, known as dysbiosis, is strongly linked to MASLD. This imbalance can lead to problems like increased inflammation and altered metabolism, which contribute to the liver disease worsening. The paper highlighted that therapies aimed at restoring a healthy gut microbiome, such as using prebiotics (types of fiber that feed beneficial bacteria) or probiotics, show promise. It also suggested that analyzing a person's gut bacteria could help detect MASLD earlier.

Dietary takeaway

While more research is always needed, this review reinforces the idea that what we eat can significantly impact our gut health and, in turn, our liver. Incorporating a variety of fiber-rich foods like fruits, vegetables, whole grains, and legumes into your daily diet can help nourish beneficial gut bacteria. This supports a balanced microbiome, which may contribute to better overall metabolic and liver health, potentially reducing the risk or progression of conditions like MASLD. However, remember that this is a review of existing studies, and individual responses can vary; one study alone doesn't provide definitive medical advice.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD), affects a substantial proportion of the global population and is closely associated with metabolic disorders. The gut microbiota, comprising a diverse community of microorganisms within the gastrointestinal tract, plays a crucial role in maintaining host health. Dysbiosis, defined as an imbalance in this microbial ecosystem, has been increasingly implicated in the development and progression of liver diseases, including MASLD. This review examines the role of the gut microbiota in MASLD pathogenesis and highlights its potential as a therapeutic target. The gut-liver axis facilitates bidirectional communication between the intestine and the liver, thereby influencing metabolic regulation. In MASLD, dysbiosis characterized by reduced microbial diversity and an increased abundance of Gram-negative bacteria leads to altered bile acid metabolism, increased intestinal permeability, enhanced endotoxin translocation, and hepatic inflammation. Additionally, it disrupts short-chain fatty acid production and interferes with the endocannabinoid system and choline metabolism, collectively driving disease progression. Emerging non-invasive diagnostic approaches, including gut microbiome profiling, show promise for early detection. Although specific pharmacological treatments remain limited, microbiota-targeted strategies such as probiotics, prebiotics, and synbiotics aim to restore microbial balance. Furthermore, emerging modalities within microbiome-based therapies, including mesenchymal stromal cell therapy and bacteriophage therapy, offer potential for targeted modulation of the gut microbiota and liver repair. The gut microbiota-liver axis plays a central role in the pathogenesis of MASLD. Growing insights into this relationship have driven the development of microbiome-based diagnostic and therapeutic approaches. Non-invasive diagnostic tools, particularly gut microbiome profiling, show promise for early detection. Therapeutically, microbiota-targeted strategies including probiotics, prebiotics, synbiotics, and emerging modalities such as cellular and bacteriophage-based therapies offer potential to restore microbial balance and improve liver function. Nevertheless, robust clinical studies are essential to validate their efficacy, safety, and applicability in personalized MASLD management.

View on PubMed →DOI: 10.1007/s13105-026-01199-7